Introduction The coronavirus disease (COVID-19) is a global health emergency. Major
disruption to healthcare services during the current COVID-19 pandemic will last even after …

Unplanned pregnancy (UP) is a public health problem, which affects millions of women
worldwide. Providing long-acting reversible contraceptive (LARC) methods is an excellent …

Background The 52-mg levonorgestrel-releasing intrauterine system is an established, long-
acting contraceptive option with approved use for up to 7 years. Objective The Mirena …

Objective To systematically review the literature to determine if extended use of intrauterine
devices, including the copper or levonorgestrel intrauterine device, beyond approved …

METHODS: A retrospective chart review was conducted for all nulliparous patients ages≤
22 with physical, intellectual, or developmental disabilities who had levonorgestrel IUDs …

The pandemic has had both positive and negative effects on access to FP services.
Innovations in various delivery services, extended use of contraception, telehealth for …

“No other contraceptive method has undergone so rapid and thorough a change of medical
reputation as that experienced by intrauterine devices over the past few years”[1]. These …

Primary care clinicians are uniquely situated to provide holistic contraceptive care. This
article addresses emergency contraception, fertility awareness methods of contraception …

In this clinical recommendation, we review the evidence supporting the use of the copper
intrauterine device, levonorgestrel intrauterine devices and etonogestrel subdermal implant …

Objective We evaluated clinical performance when the TCu380A intrauterine device (IUD)
and the levonorgestrel (LNG) 52‐mg intrauterine system (IUS) were inserted by different …